With its new treatment platform for intraoperative radiotherapy, ZEISS is actively shaping the medical innovation of neuro tumor therapy.
As a leading provider of medical solutions in the field of neurosurgery, ZEISS Medical Technology is also dedicated to shaping modern oncology. The company recently received 510(k) clearance from the US Food and Drug Administration (FDA) for INTRABEAM® 700 – a leading-edge platform that provides robotic-assisted precision to support intraoperative radiation therapy (IORT). With its modern digital-first architecture, ZEISS INTRABEAM 700 creates SMART workflow efficiency and provides seamless connectivity, offering real added value for neurooncology and breast cancer therapy.
Robotic-assisted Precision
In oncological treatments, it must be ensured that the target area is optimally resected, and that healthy tissue is spared as much as possible. Especially during contact irradiation, it is important that the target focus always remains the same throughout the entire treatment, without interruptions or unintended movements. The cutting-edge maneuverability of the brand-new robotic ZEISS INTRABEAM SMART Stand meets these clinical requirements and offers excellent positioning control at every stage of the treatment.
ZEISS INTRABEAM SMART Stand supports the precise positioning of the applicator by allowing it to approach the cavity fast, but also to slow down the speed of movement when navigating the applicator within the cavity. Once the applicator is in place, the active damping and the stand dynamics reduce residual vibrations to a minimum.
